drugset / Trial / NCT00819468

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

NCT00819468

Phase 1 Completed 24 enrolled Shire
Non-randomizedParallel-groupOpen-labelOther

Summary

This is a study to compare the pharmacokinetic profile of teduglutide in healthy participants with normal hepatic function with participants who have moderate hepatic impairment.

Timeline

Start
2007-07-26
Primary completion
2007-08-23
Completion
2007-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Teduglutide Peptide 20 mg Subcutaneous

Indications

No indication recorded.